Hyperbaric medicine

A Sechrist Monoplace hyperbaric chamber at the Moose Jaw Union Hospital, Saskatchewan, Canada

Hyperbaric medicine, also known as hyperbaric oxygen therapy (HBOT), is the medical use of oxygen at a level higher than atmospheric pressure.

Contents

Therapeutic principles

Several therapeutic principles are made use of in HBOT:[1]

Indications

Not long ago, HBOT was controversial and health policy regarding its uses was politically charged. Both sides of the issue of the effectiveness of HBOT for pathological and non-pathological use is available in the form of Cochrane Library reviews.[3] As of January, 2010, times have changed and HBOT is even being proposed to treat U.S. servicemen and women suffering with PTSD.[4] HBOT, both in the hard chambers and the soft chambers, is now seeing widespread use throughout the world for a number of acute and chronic conditions.[5]

In the United States the Undersea and Hyperbaric Medical Society, known as UHMS, lists approvals for reimbursement for certain diagnoses in hospitals and clinics. The following indications are approved (for reimbursement) uses of hyperbaric oxygen therapy as defined by the UHMS Hyperbaric Oxygen Therapy Committee:[1][6]

HBOT is recognized by Medicare in the United States as a reimbursable treatment for 14 UHMS "approved" conditions. A 1-hour HBOT session may cost between $108 and $250 in private clinics, and over $1,000 in hospitals. U.S. physicians (either M.D. or D.O.) may lawfully prescribe HBOT for "off-label" conditions such as Lyme Disease,[45] stroke,[46][47][48] and migraines.[49][50][51] Such patients are treated in outpatient clinics. In the United Kingdom most chambers are financed by the National Health Service, although some, such as those run by Multiple Sclerosis Therapy Centres, are non-profit.

Other reported applications include:

The toxicology of the treatment has recently been reviewed by Ustundag et al.[58] and its risk management is discussed by Christian R. Mortensen.[59]

Structure

Construction

In the past, the traditional type of hyperbaric chamber used for HBOT was a hard shelled pressure vessel. Such chambers can be run at absolute pressures up to 6 bars (87 psi). Navies, diving organizations and hospitals typically operate these. They range in size from semi-portable, one-patient units to large, fixed units that can treat eight or more patients. Recent advances in materials technology have resulted in the manufacture of portable, "soft" chambers that can operate at between 0.3 and 0.5 bar (4.4 and 7.3 psi) above atmospheric pressure.[60] Hard chambers and soft chambers should not be considered equivalent in regards to efficacy and safety as they are different in many aspects.

A hard chamber may consist of:

A soft chamber may consist of:

Oxygen supply

Breathing oxygen from an aviator's mask
A recompression chamber for a single diving casualty

In today's larger "multiplace" chambers, both patients and medical staff inside the chamber breathe from "oxygen helmets", flexible, transparent soft plastic helmets with a seal around the neck similar to a space suit helmet, or tightly fitting aviator's oxygen masks, which supply pure oxygen and remove the exhaled gas from the chamber. During treatment patients breathe 100% oxygen most of the time but have periodic air breaks to minimize the risk of oxygen toxicity. The exhaled gas must be removed from the chamber to prevent the build up of oxygen, which could provoke a fire. Medical staff may also breathe oxygen to reduce the risk of decompression sickness. Administration of 96% to 100% oxygen maximizes the patient's treatment. The pressure inside a hard chamber is increased by opening valves allowing high-pressure air to enter from storage cylinders, similar to diving cylinders. An air compressor is used to fill these cylinders. A soft chamber may be pressurised directly from a compressor.

Smaller "monoplace" chambers can only accommodate the patient. No medical staff can enter. The chamber is flooded with pure oxygen or compressed air. The cost of using pure oxygen in a monoplace chamber is much higher than using compressed air. If pure oxygen is used, no oxygen breathing mask or helmet is needed. If compressed air is used then an oxygen mask or helmet is needed as in a multiplace, hard chamber. In monoplace chambers that are compressed with pure oxygen a mask is available to provide the patient with "air breaks," periods of breathing normal air, in order to reduce the risk of hyperoxic seizures. In soft chambers, using compressed air and a mask supplying 96% oxygen, no air breaks are necessary as there is no risk of oxygen toxicity because of relatively low oxygen partial pressures and short durations of treatment.

Treatments

Initially, HBOT was developed as a treatment for diving disorders involving bubbles of gas in the tissues, such as decompression sickness and gas embolism. The chamber cures decompression sickness and gas embolism by increasing pressure, reducing the size of the gas bubbles and improving the transport of blood to downstream tissues. The high concentrations of oxygen in the tissues are beneficial in keeping oxygen-starved tissues alive, and have the effect of removing the nitrogen from the bubble, making it smaller until it consists only of oxygen, which is re-absorbed into the body. After elimination of bubbles, the pressure is gradually reduced back to atmospheric levels.

Protocol

The slang term, at some facilities, for a cycle of pressurization inside the HBOT chamber is "a dive". An HBOT treatment for longer-term conditions is often a series of 20 to 40 dives, or compressions. Again, these dives last for about an hour and can be administered via a hard, high-pressure chamber or a soft, low-pressure chamber - the major difference being per-dive "dose" of oxygen. Many conditions do quite well with the lower dose, lower cost-per-hour, soft chambers.

Emergency HBOT for decompression illness follows treatment schedules laid out in treatment tables. Most cases employ a recompression to 2.8 bars (41 psi) absolute, the equivalent of 18 metres (60 ft) of water, for 4.5 to 5.5 hours with the casualty breathing pure oxygen, but taking air breaks every 20 minutes to reduce oxygen toxicity. For extremely serious cases resulting from very deep dives, the treatment may require a chamber capable of a maximum pressure of 8 bars (120 psi), the equivalent of 70 metres (230 ft) of water, and the ability to supply heliox as a breathing gas.[61]

U.S. Navy treatment charts are used in Canada and the United States to determine the duration, pressure, and breathing gas of the therapy. The most frequently used tables are Table 5 and Table 6. In the UK the Royal Navy 62 and 67 tables are used.

The Undersea and Hyperbaric Medical Society (UHMS) publishes a report that compiles the latest research findings and contains information regarding the recommended duration and pressure of the longer-term conditions.[62]

Home and out-patient clinic treatment

An example of mild portable hyperbaric chamber. This 40 inch diameter chamber is one of the larger chambers available for home.
Inside a 40 inch diameter portable mild hyperbaric chamber

There are several sizes of portable HBOT chambers, which are used for home treatment. These are usually referred to as "mild personal hyperbaric chambers", which is a reference to the lower pressure (compared to hard chambers) of soft-sided chambers. Food and Drug Administration (FDA) approved chambers available in the USA go up to 4.4 pounds per square inch (psi) above atmospheric pressure, which equals 1.4 atmospheres absolute (ATA), equivalent to a depth of 13.2 feet of sea water [63] In the US, these "mild personal hyperbaric chambers" are catgorized by the FDA as CLASS II medical devices and requires a prescription in order to purchase one or take treatments.[64] Personal hyperbaric chambers are only FDA approved to reach 1.3 ATA. While hyperbaric chamber distributors and manufacturers cannot supply a chamber in the US with any form of elevated oxygen delivery system, a physician can write a prescription to combine the two modalities, as long as there is a prescription for both hyperbarics and oxygen. The most common option (but not approved by FDA) some patients choose is to acquire an oxygen concentrator which typically delivers 85–96% oxygen as the breathing gas. Due to the high circulation of air through the chamber, the total concentration of oxygen in the chamber never exceeds 25% as this can increase the risk of fire. Oxygen is never fed directly into soft chambers but is rather introduced via a line and mask directly to the patient. FDA approved oxygen concentrators for human consumption in confined areas used for HBOT are regularly monitored for purity (+/- 1%) and flow (10 to 15 liters per minute outflow pressure). An audible alarm will sound if the purity ever drops below 80%. Personal hyperbaric chambers use 120 volt or 220 volt outlets. Ranging in size from 21 inches up to 40 inches in diameter these chambers measure between 84 in (7 ft) to 120 in (10 ft) in length. The soft chambers are approved by the FDA for the treatment of altitude sickness, but are commonly used for other "off-label" purposes.

Possible complications and concerns

There are risks associated with HBOT, similar to some diving disorders. Pressure changes can cause a "squeeze" or barotrauma in the tissues surrounding trapped air inside the body, such as the lungs[65], behind the eardrum[66][67], inside paranasal sinuses[66], or trapped underneath dental fillings[68]. Breathing high-pressure oxygen may cause oxygen toxicity.[69] Temporarily blurred vision can be caused by swelling of the lens, which usually resolves in two to four weeks.[70][71]

There are reports that cataract may progress following HBOT.[72] Also a rare side effect has been blindness secondary to optic neuritis (inflammation of the optic nerve).

Effects of Pressure

Patients inside the chamber may notice discomfort inside their ears as a pressure difference develops between their middle ear and the chamber atmosphere.[73] This can be relieved by the Valsalva maneuver or by "jaw wiggling". As the pressure increases further, mist may form in the air inside the chamber and the air may become warm. When the patient speaks, the pitch of the voice may increase to the level that they sound like cartoon characters.

To reduce the pressure, a valve is opened to allow air out of the chamber. As the pressure falls, the patient’s ears may "squeak" as the pressure inside the ear equalizes with the chamber. The temperature in the chamber will fall. The speed of pressurization and de-pressurization can be adjusted to each patient's needs.

Contraindications

The only absolute contraindication to hyperbaric oxygen therapy is untreated pneumothorax.[74] Also, the treatment may raise the issue of Occupational health and safety (OHS), which has been encountered by the therapist.[75]

Patients should not undergo HBO therapy if they are taking or have recently taken the following drugs:

The following are relative contraindications -- meaning that special consideration must be made by specialist physicians before HBO treatments begin:

Neuro-rehabilitation

A father and his son inside a hyperbaric oxygen chamber.

The Collet (Quebec) trial[79] that was published in the Lancet in 2001 was the largest randomized trial of Hyperbaric Oxygen Therapy (HBOT) for children with cerebral palsy (CP); it followed the McGill pilot study on the same subject.[80]

The evidence showed both groups of children treated with two very different hyperbaric treatment dosages improved significantly. The motor improvements that were seen and measured with the gross motor function measure[81] were greater, more generalized, and were obtained in a shorter period of time than most of the changes found in any other studies of recognized conventional therapies in the treatment of children with cerebral palsy.[82][83] The children in both groups improved an average of ten times more during the two months of HBOT (whilst all other therapies and medication were stopped) than during the three months follow-up (when medication and all the ancillary treatments were restarted). This impressive change in the rate of improvements clearly indicates the probable effectiveness of hyperbaric treatment. Both the Lancet commentary[84] and the tech report by the Agency for Healthcare Research and Quality (AHRQ)[85] concluded that the hypothesis of both treatments being equally effective should be retained.

Since the Quebec study of HBOT for children with CP, many reports[86][87] have been made on the possible efficacy of a low pressure hyperbaric treatment and all the trials[88][89][90][91] conducted with HBOT in CP have demonstrated positive results.

An editorial on CP published by the Undersea and Hyperbaric Medical Society in 2007 called for further research that will include "basic science research to determine a reasonable mechanism of action" for hyperbaric oxygenation as well as "clinical studies of the highest possible methodological rigor".[92]

Some medical practitioners recommend the use of HBOT for the treatment of acute tinnitus but this treatment has not been verified by independent evidence and the treatment was withdrawn from support by the German health insurance.[93] There is evidence that the therapeutic effects could be greatly due to psychological mechanisms triggered by the patients attitude towards therapy prior to the treatment.[94]

The earliest randomized, placebo-controlled, double-blind study on multiple sclerosis patients treated with HBOT suggested the therapy could improve balance and bladder function.[95] However, by 2004 a Cochrane review assessing ten trials and 21 analyses "found no consistent evidence to confirm a beneficial effect of hyperbaric oxygen therapy for the treatment of multiple sclerosis and do not believe routine use is justified".[96]

See also

References

  1. 1.0 1.1 Gesell, Laurie B. (Chair and editor) (2008). Hyperbaric Oxygen Therapy Indications. The Hyperbaric Oxygen Therapy Committee Report (12 ed.). Durham, NC: Undersea and Hyperbaric Medical Society. ISBN 0930406230. 
  2. Jørgensen TB, Sørensen AM, Jansen EC (April 2008). "Iatrogenic systemic air embolism treated with hyperbaric oxygen therapy". Acta Anaesthesiol Scand 52 (4): 566–8. doi:10.1111/j.1399-6576.2008.01598.x. PMID 18339163. 
  3. The Cochrane Reviews. "The Cochrane Reviews". http://www.cochrane.org/. Retrieved 2008-05-16. 
  4. "HBOT Proposal to Congress". http://www.hyperbaricmedicalassociation.org/337/text/436/files/Harch_HAC_D_TBI_Off_Label_Response_090306Combined.pdf. 
  5. Harch, Paul. The Oxygen Revolution. Hatherleigh Press. ISBN 978-1-57826-237-3. 
  6. "Indications for hyperbaric oxygen therapy". Undersea & Hyperbaric Medical Society. 2007. http://www.uhms.org/Default.aspx?tabid=270. Retrieved 5 February 2010. 
  7. Undersea and Hyperbaric Medical Society. "Air or Gas Embolism". http://www.uhms.org/ResourceLibrary/Indications/AirorGasEmbolism/tabid/271/Default.aspx. Retrieved 2008-05-19. 
  8. Undersea and Hyperbaric Medical Society. "Carbon Monoxide". http://www.uhms.org/ResourceLibrary/Indications/CarbonMonoxidePoisoning/tabid/272/Default.aspx. Retrieved 2008-05-19. 
  9. Piantadosi CA (2004). "Carbon monoxide poisoning". Undersea Hyperb Med 31 (1): 167–77. PMID 15233173. http://archive.rubicon-foundation.org/4002. Retrieved 2008-05-19. 
  10. Undersea and Hyperbaric Medical Society. "Cyanide Poisoning". http://www.uhms.org/ResourceLibrary/Indications/CarbonMonoxidePoisoning/CyanidePoisoning/tabid/284/Default.aspx. Retrieved 2008-05-19. 
  11. Hall AH, Rumack BH (September 1986). "Clinical toxicology of cyanide". Ann Emerg Med 15 (9): 1067–74. doi:10.1016/S0196-0644(86)80131-7. PMID 3526995. http://linkinghub.elsevier.com/retrieve/pii/S0196-0644(86)80131-7. Retrieved 2008-05-19. 
  12. Takano T, Miyazaki Y, Nashimoto I, Kobayashi K (September 1980). "Effect of hyperbaric oxygen on cyanide intoxication: in situ changes in intracellular oxidation reduction". Undersea Biomed Res 7 (3): 191–7. PMID 7423657. http://archive.rubicon-foundation.org/2888. Retrieved 2008-05-19. 
  13. Undersea and Hyperbaric Medical Society. "Clostridal Myositis and Myonecrosis (Gas gangrene)". http://www.uhms.org/ResourceLibrary/Indications/ClostridalMyositisandMyonecrosis/tabid/273/Default.aspx. Retrieved 2008-05-19. 
  14. Hart GB, Strauss MB (1990). "Gas Gangrene - Clostridial Myonecrosis: A Review". J. Hyperbaric Med 5 (2): 125–144. http://archive.rubicon-foundation.org/4428. Retrieved 2008-05-16. 
  15. Zamboni WA, Riseman JA, Kucan JO (1990). "Management of Fournier's Gangrene and the role of Hyperbaric Oxygen". J. Hyperbaric Med 5 (3): 177–186. http://archive.rubicon-foundation.org/4431. Retrieved 2008-05-16. 
  16. Undersea and Hyperbaric Medical Society. "Crush Injury, Compartment syndrome, and other Acute Traumatic Ischemias". http://www.uhms.org/ResourceLibrary/Indications/CrushInjury/tabid/274/Default.aspx. Retrieved 2008-05-19. 
  17. Bouachour G, Cronier P, Gouello JP, Toulemonde JL, Talha A, Alquier P (August 1996). "Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial". J Trauma 41 (2): 333–9. PMID 8760546. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0022-5282&volume=41&issue=2&spage=333. Retrieved 2008-05-19. 
  18. Undersea and Hyperbaric Medical Society. "Decompression Sickness or Illness and Arterial Gas Embolism". http://www.uhms.org/ResourceLibrary/Indications/DecompressionSickness/tabid/275/Default.aspx. Retrieved 2008-05-19. 
  19. Brubakk, A. O.; T. S. Neuman (2003). Bennett and Elliott's physiology and medicine of diving, 5th Rev ed.. United States: Saunders Ltd.. pp. 800. ISBN 0702025712. 
  20. Acott, C. (1999). "A brief history of diving and decompression illness". South Pacific Underwater Medicine Society journal 29 (2). ISSN 0813-1988. OCLC 16986801. http://archive.rubicon-foundation.org/6004. Retrieved 2008-03-18. 
  21. Undersea and Hyperbaric Medical Society. "Enhancement of Healing in Selected Problem Wounds". http://www.uhms.org/ResourceLibrary/Indications/ProblemWounds/tabid/276/Default.aspx. Retrieved 2008-05-19. 
  22. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA (September 1997). "Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study". Undersea Hyperb Med 24 (3): 175–9. PMID 9308140. http://archive.rubicon-foundation.org/2279. Retrieved 2008-05-16. 
  23. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S (2004). "Hyperbaric oxygen therapy for chronic wounds". Cochrane Database Syst Rev (2): CD004123. doi:10.1002/14651858.CD004123.pub2. PMID 15106239. 
  24. Abidia A, Laden G, Kuhan G, et al. (June 2003). "The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial". Eur J Vasc Endovasc Surg 25 (6): 513–8. doi:10.1053/ejvs.2002.1911. PMID 12787692. 
  25. Kalani M, Jörneskog G, Naderi N, Lind F, Brismar K (2002). "Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up". J. Diabetes Complicat. 16 (2): 153–8. doi:10.1016/S1056-8727(01)00182-9. PMID 12039398. http://linkinghub.elsevier.com/retrieve/pii/S1056872701001829. 
  26. Chen, J (2003). "The Effects of Hyperbaric Oxygen Therapy on Diabetic Retinopathy". Investigative Ophthalmology & Visual Science 44 (5): 4017–B720. http://abstracts.iovs.org/cgi/content/abstract/44/5/4017. Retrieved 16 December 2008. 
  27. Chang, Yun-Hsiang et al (006). "Hyperbaric oxygen therapy ameliorates the blood–retinal barrier breakdown in diabetic retinopathy". Clinical & Experimental Ophthalmology 34 (6): 584–589. http://www3.interscience.wiley.com/journal/118585162/abstract. Retrieved 16 December 2008. 
  28. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A (2002). "Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series". J. Nephrol. 15 (6): 676–80. PMID 12495283. 
  29. Undersea and Hyperbaric Medical Society. "Exceptional Blood Loss - Anemia". http://www.uhms.org/ResourceLibrary/Indications/ExceptionalBloodLossAnemia/tabid/277/Default.aspx. Retrieved 2008-05-19. 
  30. Hart GB, Lennon PA, Strauss MB. (1987). "Hyperbaric oxygen in exceptional acute blood-loss anemia". J. Hyperbaric Med 2 (4): 205–210. http://archive.rubicon-foundation.org/4352. Retrieved 2008-05-19. 
  31.  ;Undersea and Hyperbaric Medical Society. "Intracranial Abscess". http://www.uhms.org/ResourceLibrary/Indications/IntracranialAbscess/tabid/278/Default.aspx. Retrieved 2008-05-19. 
  32. Lampl LA, Frey G, Dietze T, Trauschel M. (1989). "Hyperbaric Oxygen in Intracranial Abscesses". J. Hyperbaric Med 4 (3): 111–126. http://archive.rubicon-foundation.org/4352. Retrieved 2008-05-19. 
  33. Undersea and Hyperbaric Medical Society. "Necrotizing Soft Tissue Infections". http://www.uhms.org/ResourceLibrary/Indications/NecrotizingSoftTissueInfections/tabid/279/Default.aspx. Retrieved 2008-05-19. 
  34. Escobar SJ, Slade JB, Hunt TK, Cianci P (2005). "Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate". Undersea Hyperb Med 32 (6): 437–43. PMID 16509286. http://archive.rubicon-foundation.org/4061. Retrieved 2008-05-16. 
  35. Undersea and Hyperbaric Medical Society. "Refractory Osteomyelitis". http://www.uhms.org/ResourceLibrary/Indications/OsteomyelitisRefractory/tabid/280/Default.aspx. Retrieved 2008-05-19. 
  36. Mader JT, Adams KR, Sutton TE (1987). "Infectious diseases: pathophysiology and mechanisms of hyperbaric oxygen". J. Hyperbaric Med 2 (3): 133–140. http://archive.rubicon-foundation.org/4339. Retrieved 2008-05-16. 
  37. Kawashima M, Tamura H, Nagayoshi I, Takao K, Yoshida K, Yamaguchi T (2004). "Hyperbaric oxygen therapy in orthopedic conditions". Undersea Hyperb Med 31 (1): 155–62. PMID 15233171. http://archive.rubicon-foundation.org/4000. Retrieved 2008-05-16. 
  38. Undersea and Hyperbaric Medical Society. "Hyperbaric Ocxgen Treatments for Complications of radiation Therapy". http://www.uhms.org/ResourceLibrary/Indications/DelayedRadiationInjury/tabid/281/Default.aspx. Retrieved 2008-05-19. 
  39. Zhang, L. D.; J. F. Kang; H. L. Xue. (1990). "Distribution of lesions in the head and neck of the humerus and the femur in dysbaric osteonecrosis". Undersea Biomed. Res. 17 (4): 353–358. ISSN 0093-5387. OCLC 2068005. PMID 2396333. http://archive.rubicon-foundation.org/2570. Retrieved 2008-04-06. 
  40. Lafforgue, P., Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine, 2006. 73(5): p. 500–7.
  41. Undersea and Hyperbaric Medical Society. "Skin Grafts and Flaps Compromised". http://www.uhms.org/ResourceLibrary/Indications/SkinGraftsFlaps/tabid/282/Default.aspx. Retrieved 2008-05-19. 
  42. McFarlane RM, Wermuth RE (May 1966). "The use of hyperbaric oxygen to prevent necrosis in experimental pedicle flaps and composite skin grafts". Plast. Reconstr. Surg. 37 (5): 422–30. doi:10.1097/00006534-196605000-00008. PMID 5327032. 
  43. Undersea and Hyperbaric Medical Society. "Thermal Burns". http://www.uhms.org/ResourceLibrary/Indications/ThermalBurns/tabid/283/Default.aspx. Retrieved 2008-05-19. 
  44. Cianci P, Lueders H, Lee H, Shapiro R, Sexton J, Williams C, Green B (1988). "Adjunctive Hyperbaric Oxygen Reduces the Need for Surgery in 40–80% Burns". J. Hyperbaric Med 3 (2): 97–101. http://archive.rubicon-foundation.org/4369. Retrieved 2008-05-16. 
  45. Taylor RS, Simpson IN (September 2005). "Review of treatment options for lyme borreliosis". J Chemother 17 Suppl 2: 3–16. PMID 16315580. http://www.jchemother.it/cgi-bin/digisuite.exe/searchresult?range=pubmed&volume=17%20Suppl%202&year=2005&firstpage=3. Retrieved 2008-08-06. 
  46. Bennett MH, Wasiak J, Schnabel A, Kranke P, French C (2005). "Hyperbaric oxygen therapy for acute ischaemic stroke". Cochrane Database Syst Rev (3): CD004954. doi:10.1002/14651858.CD004954.pub2. PMID 16034959. 
  47. Jain KK (1989). "Effect of Hyperbaric Oxygenation on Spasticity in Stroke Patients.". J. Hyperbaric Med 4 (2): 55–61. http://archive.rubicon-foundation.org/4394. Retrieved 2008-08-06. 
  48. Singhal AB, Lo EH (February 2008). "Advances in emerging nondrug therapies for acute stroke 2007". Stroke 39 (2): 289–91. doi:10.1161/STROKEAHA.107.511485. PMID 18187678. http://stroke.ahajournals.org/cgi/pmidlookup?view=long&pmid=18187678. Retrieved 2008-08-06. 
  49. Bennett MH, French C, Schnabel A, Wasiak J, Kranke P (2008). "Normobaric and hyperbaric oxygen therapy for migraine and cluster headache". Cochrane Database Syst Rev (3): CD005219. doi:10.1002/14651858.CD005219.pub2. PMID 18646121. 
  50. Eftedal OS, Lydersen S, Helde G, White L, Brubakk AO, Stovner LJ (2004). "A randomized, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine". Cephalalgia 24 (8): 639–44. doi:10.1111/j.1468-2982.2004.00724.x. PMID 15265052. 
  51. Fife WP, Fife CE (1989). "Treatment of Migraine with Hyperbaric Oxygen.". J. Hyperbaric Med 4 (1): 7–15. http://archive.rubicon-foundation.org/4386. Retrieved 2008-08-06. 
  52. Rossignol DA, Rossignol LW, Smith S et al. (2009). "Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial" (PDF). BMC Pediatrics 9: 21. doi:10.1186/1471-2431-9-21. PMID 19284641. PMC 2662857. http://www.biomedcentral.com/content/pdf/1471-2431-9-21.pdf. Lay summary – BBC News (2009-03-14). 
  53. Baechli H, Schmutz J, Mayr JM (2008). "Hyperbaric oxygen therapy (HBO) for the treatment of an epidural abscess in the posterior fossa in an 8-month-old infant". Pediatr Neurosurg 44 (3): 239–42. doi:10.1159/000121383. PMID 18354266. 
  54. Suzuki H, Fujimura T, Shiomori T, et al. (June 2008). "Prostaglandin E1 versus steroid in combination with hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss". Auris Nasus Larynx 35 (2): 192–7. doi:10.1016/j.anl.2007.06.003. PMID 17826927. 
  55. Yoshida, Takahiro et al.; Kawashima, A; Ujike, T; Uemura, M; Nishimura, K; Miyoshi, S (2008). "Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis". International Journal of Urology 15 (7): 639–641. doi:10.1111/j.1442-2042.2008.02053.x. PMID 18643783. 
  56. Noyer, Charles M. et al.; Brandt, LJ (2004). "Hyperbaric oxygen therapy for perineal Crohn's disease". The American Journal of Gastroenterology 94 (2): 318–321. doi:10.1111/j.1572-0241.1999.00848.x. PMID 10022622. 
  57. Atug, Ozlen et al.; Hamzaoglu, H; Tahan, V; Alican, I; Kurtkaya, O; Elbuken, E; Ozdogan, O; Tozun, N (2008). "Hyperbaric Oxygen Therapy Is as Effective as Dexamethasone in the Treatment of TNBS-E-Induced Experimental Colitis". Digestive Diseases and Sciences 53 (2): 481–485. doi:10.1007/s10620-007-9956-4. PMID 17934837. 
  58. Ustundag, Aylin et al.; Duydu, Y; Aydin, A; Eken, A; Dundar, K; Uzun, G (2008). "Evaluation of the potential genotoxic effects of hyperbaric oxygen therapy". Toxicology Letters 180 (Supplement 1): S142. doi:10.1016/j.toxlet.2008.06.792. 
  59. Mortensen, Christian Risby (2008). "Hyperbaric oxygen therapy". Current Anaesthesia & Critical Care (Elsevier) 19 (5–6): 333–337. doi:10.1016/j.cacc.2008.07.007. 
  60. [1]
  61. U.S. Navy Supervisor of Diving (2008). U.S. Navy Diving Manual. SS521-AG-PRO-010, revision 6. U.S. Naval Sea Systems Command. pp. 37–49. http://supsalv.org/pdf/DiveMan_rev6.pdf. Retrieved 2009-06-29. 
  62. Undersea and Hyperbaric Medical Society
  63. cite web url - http://www.rescuediver.org/med/phys.htm
  64. Broome JR, Smith DJ (November 1992). "Pneumothorax as a complication of recompression therapy for cerebral arterial gas embolism". Undersea Biomed Res 19 (6): 447–55. PMID 1304671. http://archive.rubicon-foundation.org/2600. Retrieved 2008-05-23. 
  65. 66.0 66.1 Fitzpatrick DT, Franck BA, Mason KT, Shannon SG (1999). "Risk factors for symptomatic otic and sinus barotrauma in a multiplace hyperbaric chamber". Undersea Hyperb Med 26 (4): 243–7. PMID 10642071. http://archive.rubicon-foundation.org/2316. Retrieved 2008-05-23. 
  66. Fiesseler FW, Silverman ME, Riggs RL, Szucs PA (2006). "Indication for hyperbaric oxygen treatment as a predictor of tympanostomy tube placement". Undersea Hyperb Med 33 (4): 231–5. PMID 17004409. http://archive.rubicon-foundation.org/5033. Retrieved 2008-05-23. 
  67. Stein, L (2000). "Dental Distress. The ‘Diving Dentist’ Addresses the Problem of a Diving-Related Toothache" (PDF). Alert Diver (January/ February): 45–48. http://www.diversalertnetwork.org/membership/alert-diver/articles/public/AlertDiver_JF00_45-48.PDF. Retrieved 2008-05-23. 
  68. Smerz, R.W. (2004). "Incidence of oxygen toxicity during the treatment of dysbarism". Undersea and Hyperbaric Medicine 31 (2): 199–202. PMID 15485081. http://archive.rubicon-foundation.org/4010. Retrieved 2008-04-30. 
  69. Butler FK (1995). "Diving and hyperbaric ophthalmology". Surv Ophthalmol 39 (5): 347–66. doi:10.1016/S0039-6257(05)80091-8. PMID 7604359. 
  70. Butler FK, White E, Twa M (1999). "Hyperoxic myopia in a closed-circuit mixed-gas scuba diver". Undersea Hyperb Med 26 (1): 41–5. PMID 10353183. http://archive.rubicon-foundation.org/2312. Retrieved 2008-05-23. 
  71. Gesell LB, Adams BS, and Kob DG (2000). "De Novo Cataract Development Following A Standard Course Of Hyperbaric Oxygen Therapy". Undersea Hyperb Med abstract 27 (supplement). http://archive.rubicon-foundation.org/6862. Retrieved 2008-06-01. 
  72. Lehm Jan P, Bennett Michael H (2003). "Predictors of middle ear barotrauma associated with hyperbaric oxygen therapy". South Pacific Underwater Medicine Society Journal 33: 127–133. http://archive.rubicon-foundation.org/8076. Retrieved 2009-07-15. 
  73. Broome JR, Smith DJ (November 1992). "Pneumothorax as a complication of recompression therapy for cerebral arterial gas embolism". Undersea Biomed Res 19 (6): 447–55. PMID 1304671. http://archive.rubicon-foundation.org/2600. Retrieved 2008-05-23. 
  74. CAMJ (2008). "Fracture of the maxillary bone during hyperbaric oxygen therapy". http://www.ecmaj.ca/cgi/reprint/179/12/1351. Retrieved 17 December 2008. 
  75. Takenaka S, Arimura T, Higashi M, Nagayama T, Ito E (August 1980). "Experimental study of bleomycin therapy in combination with hyperbaric oxygenation". Nippon Gan Chiryo Gakkai Shi 15 (5): 864–75. PMID 6159432. 
  76. Stubbs JM, Johnson EG, Thom SR (2005). "Trends Of Treating Patients, That Have Received Bleomycin Therapy In The Past, With Hyperbaric Oxygen Treatment (Hbot) And A Survey Of Considered Absolute Contraindications To Hbot". Undersea Hyperb Med abstract 32 (supplement). http://archive.rubicon-foundation.org/1638. Retrieved 2008-05-23. 
  77. Feldmeier J, Carl U, Hartmann K, and Sminia P. (Spring 2003). "Hyperbaric Oxygen: Does it promote growth or recurrence of malignancy?". Undersea and Hyperbaric Medicine 30 (1): 1–18. PMID 12841604. 
  78. Collet, J.P., Vanasse, M., Marois, P., Amar, M., Goldberg, J., Lambert, J. et al. (2001) Hyperbaric oxygen for children with cerebral palsy: A randomized multicentre trial. The Lancet, 357, 582–586.
  79. Montgomery D, Goldberg J, Amar M, Lacroix V, Lecomte J, Lambert J, Vanasse M, Marois P (1999). "Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: a pilot project". Undersea Hyperb Med 26 (4): 235–42. PMID 10642070. http://archive.rubicon-foundation.org/2324. Retrieved 2008-06-17. 
  80. Russell, D.J., Rosenbaum, P.L., Cadman, D.T., Gowland, C., Hardy, S., & Jarvis, S. (1989). The gross motor function measure: A means to evaluate the effects of physical therapy. Developmental Medicine & Child Neurology, 31(3), 341–352.
  81. Almeida, G.L., Campbell, S.K., Girolami, G.L., Penn, R.D., & Corcos, D.M. (1997). Multidimensional assessment of motor function in a child with cerebral palsy following intrathecal administration of baclofen. Physical Therapy, 77 (7), 751–764.
  82. Damiano, D.L. & Abel, M.F. (1998). Functional outcomes of strength training in spastic cerebral palsy. Archives of Physical Medicine and Rehabilitation, 79 (2), 119–125.
  83. Talking Points, Hyperbaric oxygen: Hype or hope? Lancet 2001;357
  84. Agency for Healthcare US Department. (2003). "Hyperbaric Oxygen Therapy for Brain Injury, Cerebral Palsy, and Stroke". http://www.ahrq.gov/clinic/epcsums/hypoxsum.htm. Retrieved 2008-06-17. 
  85. Chang CF, Niu KC, Hoffer BJ, Wang Y, Borlongan CV. Hyperbaric oxygen therapy for treatment of post ischemic stroke in adult rats. Exp Neurol 2002; 166: 298–306.
  86. Heuser G, Heuser SA, Rodelander D, Aguilera O, Uszler M. Treatment of neurologically impaired adults and children with "mild" hyperbaric oxygenation (1.3 ATA and 24% Oxygen). In Joiner JT, ed. Hyperbaric Oxygenation for Cerebral Palsy and the Brain-Injured Child. Best Publications, Flagstaff Arizona 2002;109–15
  87. Barret, K. (1999). Pediatric cerebral palsy treated by 1.5 ATA hyperbaric oxygen – A pilot study. Proceedings of The Second International Symposium on HBO for CP .
  88. Marois, P., & Vanasse, M. (Juillet 2006). HBOT in the treatment of cerebral palsy: A retrospective study of 120 cases-5 years. Paper presented at 5th Annual Symposium: HBO and the recoverable brain, Fort Lauderdale, USA.
  89. Nighoghossian N., Trouillas P., Adeleine P., Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke. Stroke 1995; 26: 1369–1372.
  90. SHI Xiao-yan, TANG Zhong-quan, SUN Da and HE Xiao-jun. Evaluation of hyperbaric oxygen treatment of neuropsychiatric disorders following traumatic brain injury. Chin Med J 2006;119(23):1978–1982.
  91. Bennett M, Newton H (2007). "Hyperbaric oxygen therapy and cerebral palsy--where to now?". Undersea Hyperb Med 34 (2): 69–74. PMID 17520857. http://archive.rubicon-foundation.org/6469. Retrieved 2008-04-20. 
  92. Sümmerer H. "Idiopathic tinnitus /sudden deafness". HBO Center Traunstein. http://www.druckkammerzentrum-traunstein.de/Englisch/HBO_Tinnitus_engl.htm. Retrieved 2008-06-19. 
  93. Stiegler P, Matzi V, Lipp C, Kontaxis A, Klemen H, Walch C, Smolle-Jüttner F (2006). "Hyperbaric oxygen (HBO2) in tinnitus: influence of psychological factors on treatment results?". Undersea Hyperb Med 33 (6): 429–37. PMID 17274312. http://archive.rubicon-foundation.org/5044. Retrieved 2008-06-19. 
  94. Fischer BH, Marks M, Reich T (January 1983). "Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study". N. Engl. J. Med. 308 (4): 181–6. PMID 6336824. 
  95. Bennett M, Heard R (2004). "Hyperbaric oxygen therapy for multiple sclerosis". Cochrane Database Syst Rev (1): CD003057. doi:10.1002/14651858.CD003057.pub2. PMID 14974004. 

Further reading

External links